|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.
|
|
2
|
Saintigny P and Burger JA: Recent advances
in non-small cell lung cancer biology and clinical management.
Discov Med. 13:287–297. 2012.
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.
|
|
4
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008.
|
|
5
|
Collins LG, Haines C, Perkel R and Enck
RE: Lung cancer: diagnosis and management. Am Fam Physician.
75:56–63. 2007.
|
|
6
|
Nilsson J, Vallbo C, Guo D, et al:
Cloning, characterization, and expression of human LIG1. Biochem
Biophys Res Commun. 284:1155–1161. 2001.
|
|
7
|
Holmlund C, Nilsson J, Guo D, et al:
Characterization and tissue-specific expression of human LRIG2.
Gene. 332:35–43. 2004.
|
|
8
|
Guo D, Holmlund C, Henriksson R and Hedman
H: The LRIG gene family has three vertebrate paralogs widely
expressed in human and mouse tissues and a homolog in Ascidiacea.
Genomics. 84:157–165. 2004.
|
|
9
|
Hedman H and Henriksson R: LRIG inhibitors
of growth factor signalling - double-edged swords in human cancer?
Eur J Cancer. 43:676–682. 2007.
|
|
10
|
Thomasson M, Hedman H, Guo D, Ljungberg B
and Henriksson R: LRIG1 and epidermal growth factor receptor in
renal cell carcinoma: A quantitative RT-PCR and immunohistochemical
analysis. Br J Cancer. 89:1285–1289. 2003.
|
|
11
|
Krig SR, Frietze S, Simion C, et al: Lrig1
is an estrogen-regulated growth suppressor and correlates with
longer relapse-free survival in ERalpha-positive breast cancer. Mol
Cancer Res. 9:1406–1417. 2011.
|
|
12
|
Lindstrom AK, Ekman K, Stendahl U, et al:
LRIG1 and squamous epithelial uterine cervical cancer: correlation
to prognosis, other tumor markers, sex steroid hormones, and
smoking. Int J Gynecol Cancer. 18:312–317. 2008.
|
|
13
|
Tanemura A, Nagasawa T, Inui S and Itami
S: LRIG-1 provides a novel prognostic predictor in squamous cell
carcinoma of the skin: immunohistochemical analysis for 38 cases.
Dermatol Surg. 31:423–430. 2005.
|
|
14
|
Holmlund C, Haapasalo H, Yi W, et al:
Cytoplasmic LRIG2 expression is associated with poor
oligodendroglioma patient survival. Neuropathology. 29:242–247.
2009.
|
|
15
|
Hedman H, Lindstrom AK, Tot T, Stendahl U,
Henriksson R and Hellberg D: LRIG2 in contrast to LRIG1 predicts
poor survival in early-stage squamous cell carcinoma of the uterine
cervix. Acta Oncol. 49:812–815. 2010.
|
|
16
|
Muller S, Lindquist D, Kanter L, et al:
Expression of LRIG1 and LRIG3 correlates with human papillomavirus
status and patient survival in cervical adenocarcinoma. Int J
Oncol. 42:247–252. 2013.
|
|
17
|
Guo D, Nilsson J, Haapasalo H, et al:
Perinuclear leucine-rich repeats and immunoglobulin-like domain
proteins (LRIG1–3) as prognostic indicators in astrocytic tumors.
Acta Neuropathol. 111:238–246. 2006.
|
|
18
|
Shimosato Y: Histological typing of lung
and pleural tumors (3rd edition, 1999): Malignant epithelial
tumors. Nihon Rinsho. 60:123–131. 2002.(In Japanese).
|
|
19
|
Kontos CK, Papadopoulos IN, Fragoulis EG
and Scorilas A: Quantitative expression analysis and prognostic
significance of L-DOPA decarboxylase in colorectal adenocarcinoma.
Br J Cancer. 102:1384–1390. 2010.
|
|
20
|
Wang B, Han L, Chen R, et al:
Downregulation of LRIG2 expression by RNA interference inhibits
glioblastoma cell (GL15) growth, causes cell cycle redistribution,
increases cell apoptosis and enhances cell adhesion and invasion
in vitro. Cancer Biol Ther. 8:1018–1023. 2009.
|
|
21
|
Lindstrom AK, Asplund A and Hellberg D:
Correlation between LRIG1 and LRIG2 expressions and expression of
11 tumor markers, with special reference to tumor suppressors, in
CIN and normal cervical epithelium. Gynecol Oncol. 122:372–376.
2011.
|
|
22
|
Ghasimi S, Haapasalo H, Eray M, et al:
Immunohistochemical analysis of LRIG proteins in meningiomas:
correlation between estrogen receptor status and LRIG expression. J
Neurooncol. 108:435–441. 2012.
|
|
23
|
Kazmi N, Marquez-Garban DC, Aivazyan L, et
al: The role of estrogen, progesterone and aromatase in human
non-small-cell lung cancer. Lung Cancer Manag. 1:259–272. 2012.
|
|
24
|
Liu B, Zheng Y, Wang TD, et al: Proteomic
identification of common SCF ubiquitin ligase FBXO6-interacting
glycoproteins in three kinds of cells. J Proteome Res.
11:1773–1781. 2012.
|
|
25
|
Zhang YW, Brognard J, Coughlin C, et al:
The F box protein Fbx6 regulates Chk1 stability and cellular
sensitivity to replication stress. Mol Cell. 35:442–453. 2009.
|
|
26
|
Zhang H, Yan Q, Xu S, et al: Association
of expression of Leucine-rich repeats and immunoglobulin-like
domains 2 gene with invasiveness of pituitary adenoma. J Huazhong
Univ Sci Technolog Med Sci. 31:520–523. 2011.
|
|
27
|
Wu X, Hedman H, Bergqvist M, et al:
Expression of EGFR and LRIG proteins in oesophageal carcinoma with
emphasis on patient survival and cellular chemosensitivity. Acta
Oncol. 51:69–76. 2012.
|
|
28
|
Musacchio M and Perrimon N: The Drosophila
kekkon genes: novel members of both the leucine-rich repeat and
immunoglobulin superfamilies expressed in the CNS. Dev Biol.
178:63–76. 1996.
|
|
29
|
Eisenstat DD and Gibson SB: RIGging
functional outcomes in glioma cells: new insights into LRIG
proteins in malignant gliomas. Cancer Biol Ther. 8:1024–1026.
2009.
|
